These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 22957504)

  • 1. Circulating lymphangiogenic factors in preeclampsia.
    Lely AT; Salahuddin S; Holwerda KM; Karumanchi SA; Rana S
    Hypertens Pregnancy; 2013; 32(1):42-9. PubMed ID: 22957504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PP016. Circulating lymphangiogenic factors in preeclampsia.
    Lely T; Salahuddin S; Holwerda K; Karumanchi A; Rana S
    Pregnancy Hypertens; 2012 Jul; 2(3):249-50. PubMed ID: 26105339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute pyelonephritis during pregnancy changes the balance of angiogenic and anti-angiogenic factors in maternal plasma.
    Chaiworapongsa T; Romero R; Gotsch F; Kusanovic JP; Mittal P; Kim SK; Erez O; Vaisbuch E; Mazaki-Tovi S; Kim CJ; Dong Z; Yeo L; Hassan SS
    J Matern Fetal Neonatal Med; 2010 Feb; 23(2):167-78. PubMed ID: 20213923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate.
    Romero R; Nien JK; Espinoza J; Todem D; Fu W; Chung H; Kusanovic JP; Gotsch F; Erez O; Mazaki-Tovi S; Gomez R; Edwin S; Chaiworapongsa T; Levine RJ; Karumanchi SA
    J Matern Fetal Neonatal Med; 2008 Jan; 21(1):9-23. PubMed ID: 18175241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age.
    Erez O; Romero R; Espinoza J; Fu W; Todem D; Kusanovic JP; Gotsch F; Edwin S; Nien JK; Chaiworapongsa T; Mittal P; Mazaki-Tovi S; Than NG; Gomez R; Hassan SS
    J Matern Fetal Neonatal Med; 2008 May; 21(5):279-87. PubMed ID: 18446652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma concentrations of angiogenic/anti-angiogenic factors have prognostic value in women presenting with suspected preeclampsia to the obstetrical triage area: a prospective study.
    Chaiworapongsa T; Romero R; Korzeniewski SJ; Cortez JM; Pappas A; Tarca AL; Chaemsaithong P; Dong Z; Yeo L; Hassan SS
    J Matern Fetal Neonatal Med; 2014 Jan; 27(2):132-44. PubMed ID: 23687930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VEGF and its soluble receptor VEGFR-2 in hypertensive disorders during pregnancy: the Indian scenario.
    Rath G; Tripathi R
    J Hum Hypertens; 2012 Mar; 26(3):196-204. PubMed ID: 21412269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unexplained fetal death: another anti-angiogenic state.
    Espinoza J; Chaiworapongsa T; Romero R; Kim YM; Kim GJ; Nien JK; Kusanovic JP; Erez O; Bujold E; Gonçalves LF; Gomez R; Edwin S
    J Matern Fetal Neonatal Med; 2007 Jul; 20(7):495-507. PubMed ID: 17674262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The association of circulating angiogenic factors and HbA1c with the risk of preeclampsia in women with preexisting diabetes.
    Cohen AL; Wenger JB; James-Todd T; Lamparello BM; Halprin E; Serdy S; Fan S; Horowitz GL; Lim KH; Rana S; Takoudes TC; Wyckoff JA; Thadhani R; Karumanchi SA; Brown FM
    Hypertens Pregnancy; 2014 Feb; 33(1):81-92. PubMed ID: 24354578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dysregulation of circulating autoantibodies against VEGF-A, VEGFR-1 and PlGF in preeclampsia - A role in placental and vascular health?
    Moe K; Heidecke H; Dechend R; Staff AC
    Pregnancy Hypertens; 2017 Oct; 10():83-89. PubMed ID: 29153696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence supporting that the excess of the sVEGFR-1 concentration in maternal plasma in preeclampsia has a uterine origin.
    Bujold E; Romero R; Chaiworapongsa T; Kim YM; Kim GJ; Kim MR; Espinoza J; Gonçalves LF; Edwin S; Mazor M
    J Matern Fetal Neonatal Med; 2005 Jul; 18(1):9-16. PubMed ID: 16105786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroblastoma progression correlates with downregulation of the lymphangiogenesis inhibitor sVEGFR-2.
    Becker J; Pavlakovic H; Ludewig F; Wilting F; Weich HA; Albuquerque R; Ambati J; Wilting J
    Clin Cancer Res; 2010 Mar; 16(5):1431-41. PubMed ID: 20179233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Lymphangiogenic Factors With Pulmonary Arterial Hypertension in Systemic Sclerosis.
    Didriksen H; Molberg Ø; Fretheim H; Gude E; Jordan S; Brunborg C; Palchevskiy V; Garen T; Midtvedt Ø; Andreassen AK; Distler O; Belperio J; Hoffmann-Vold AM
    Arthritis Rheumatol; 2021 Jul; 73(7):1277-1287. PubMed ID: 33497027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maternal serum-soluble vascular endothelial growth factor receptor-1 in early pregnancy ending in preeclampsia or intrauterine growth retardation.
    Wathén KA; Tuutti E; Stenman UH; Alfthan H; Halmesmäki E; Finne P; Ylikorkala O; Vuorela P
    J Clin Endocrinol Metab; 2006 Jan; 91(1):180-4. PubMed ID: 16263826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia.
    Koga K; Osuga Y; Yoshino O; Hirota Y; Ruimeng X; Hirata T; Takeda S; Yano T; Tsutsumi O; Taketani Y
    J Clin Endocrinol Metab; 2003 May; 88(5):2348-51. PubMed ID: 12727995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential expression of Vegfr-2 and its soluble form in preeclampsia.
    Munaut C; Lorquet S; Pequeux C; Coulon C; Le Goarant J; Chantraine F; Noël A; Goffin F; Tsatsaris V; Subtil D; Foidart JM
    PLoS One; 2012; 7(3):e33475. PubMed ID: 22428059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia.
    Chaiworapongsa T; Romero R; Kim YM; Kim GJ; Kim MR; Espinoza J; Bujold E; Gonçalves L; Gomez R; Edwin S; Mazor M
    J Matern Fetal Neonatal Med; 2005 Jan; 17(1):3-18. PubMed ID: 15804781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The maternal plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated in SGA and the magnitude of the increase relates to Doppler abnormalities in the maternal and fetal circulation.
    Chaiworapongsa T; Espinoza J; Gotsch F; Kim YM; Kim GJ; Goncalves LF; Edwin S; Kusanovic JP; Erez O; Than NG; Hassan SS; Romero R
    J Matern Fetal Neonatal Med; 2008 Jan; 21(1):25-40. PubMed ID: 18175242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of angiogenic biomarkers in maternal blood to identify which SGA fetuses will require a preterm delivery and mothers who will develop pre-eclampsia.
    Chaiworapongsa T; Romero R; Whitten AE; Korzeniewski SJ; Chaemsaithong P; Hernandez-Andrade E; Yeo L; Hassan SS
    J Matern Fetal Neonatal Med; 2016; 29(8):1214-28. PubMed ID: 26303962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum levels of platelet endothelial cell adhesion molecule-1 (PECAM-1) and soluble vascular endothelial growth factor receptor (sVEGFR)-1 and -2 in HIV associated preeclampsia.
    Thakoordeen S; Moodley J; Naicker T
    Hypertens Pregnancy; 2017 May; 36(2):168-174. PubMed ID: 28609170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.